COMPOUND PROFILE / SMALL MOLECULES
GSBR-1290.
Research draftGSBR-1290, also called aleniglipron, is an oral small-molecule GLP-1 receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
GSBR-1290, also called aleniglipron, is an oral small-molecule GLP-1 receptor agonist.
Mechanism
It is designed to activate GLP-1 signalling without a peptide structure.
Human research
Registered human development studies exist. Registration alone does not establish efficacy or the most recent programme result.
Preclinical & other research
Preclinical work supports the target rationale.
Safety & unknowns
Trial-specific adverse effects and longer exposure require assessment before broad safety claims.
Regulatory status
Investigational; use the confirmed alias to follow updated trials.
Reported use & evidence
The supplied GSBR-1290 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.